Cargando…

(694) Preservation of Lung Function Despite Covid-19 Infection in a Cohort of Lung Transplant Recipients

PURPOSE: Respiratory viruses contribute to chronic lung allograft dysfunction (CLAD). Limited data is available regarding allograft function following COVID-19. We evaluated the effect of COVID-19 on lung function trajectory in Lung Transplant Recipients (LTR). METHODS: Data was retrospectively coll...

Descripción completa

Detalles Bibliográficos
Autores principales: Ennis, S.L., Levvey, B., Shingles, H., Holsworth, L., Snell, G., Gardiner, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068095/
http://dx.doi.org/10.1016/j.healun.2023.02.708
_version_ 1785018615356981248
author Ennis, S.L.
Levvey, B.
Shingles, H.
Holsworth, L.
Snell, G.
Gardiner, B.
author_facet Ennis, S.L.
Levvey, B.
Shingles, H.
Holsworth, L.
Snell, G.
Gardiner, B.
author_sort Ennis, S.L.
collection PubMed
description PURPOSE: Respiratory viruses contribute to chronic lung allograft dysfunction (CLAD). Limited data is available regarding allograft function following COVID-19. We evaluated the effect of COVID-19 on lung function trajectory in Lung Transplant Recipients (LTR). METHODS: Data was retrospectively collected at our lung transplant (LTx) center on all LTR with confirmed COVID-19 infection between March 2020-Sept 2022. Spirometry was compared pre and post infection. Risk factors for a decline in FEV1 ≥10% were explored with logistic regression. RESULTS: From a cohort of 650 LTR, there were 224 COVID infections in 216 patients. Median age was 60 years, 118 (54%) were male and the majority were bilateral LTR (122, 88%). Median time from LTx to diagnosis was 5.2 years (IQR 2.8-10). At baseline, 187 patients (85%) received > 3 vaccines and 35 (16%) had tixagevimab/ cilgavimab. Anti-viral therapy was given in 190/216 (88%), most commonly remdesevir 93/216 (43%). 42 patients (19%) were hospitalised, 10 (5%) admitted to ICU and direct COVID related mortality was 8/216 (4%). Pre and post lung function was available on 144 patients. Median time from baseline spirometry to COVID-19 was 2.7 months and 2.2 months post COVID-19. There was a small but statistically significant decline in forced expiratory volume in 1 second (FEV1) post COVID-19, with a median drop of 0.05L (2% decline; IQR -5.6-1.8%, p<0.001); (Figure 1). A ≥10% decline in FEV1 occurred in 24/144 patients (17%) and an increase in FEV1 of >10% occurred in 6/151 (3%) of patients. Baseline demographics, lung function, disease severity, vaccination status and treatment type were not associated with a ≥10% decline in FEV1. CONCLUSION: In COVID optimized LTR with subsequent infection, the majority had mild disease. Reassuringly, most had stable lung function 2 months post infection. A small proportion had a decline in FEV1 of >10%, but there were no discernible risk factors to predict the decline.
format Online
Article
Text
id pubmed-10068095
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-100680952023-04-03 (694) Preservation of Lung Function Despite Covid-19 Infection in a Cohort of Lung Transplant Recipients Ennis, S.L. Levvey, B. Shingles, H. Holsworth, L. Snell, G. Gardiner, B. J Heart Lung Transplant Article PURPOSE: Respiratory viruses contribute to chronic lung allograft dysfunction (CLAD). Limited data is available regarding allograft function following COVID-19. We evaluated the effect of COVID-19 on lung function trajectory in Lung Transplant Recipients (LTR). METHODS: Data was retrospectively collected at our lung transplant (LTx) center on all LTR with confirmed COVID-19 infection between March 2020-Sept 2022. Spirometry was compared pre and post infection. Risk factors for a decline in FEV1 ≥10% were explored with logistic regression. RESULTS: From a cohort of 650 LTR, there were 224 COVID infections in 216 patients. Median age was 60 years, 118 (54%) were male and the majority were bilateral LTR (122, 88%). Median time from LTx to diagnosis was 5.2 years (IQR 2.8-10). At baseline, 187 patients (85%) received > 3 vaccines and 35 (16%) had tixagevimab/ cilgavimab. Anti-viral therapy was given in 190/216 (88%), most commonly remdesevir 93/216 (43%). 42 patients (19%) were hospitalised, 10 (5%) admitted to ICU and direct COVID related mortality was 8/216 (4%). Pre and post lung function was available on 144 patients. Median time from baseline spirometry to COVID-19 was 2.7 months and 2.2 months post COVID-19. There was a small but statistically significant decline in forced expiratory volume in 1 second (FEV1) post COVID-19, with a median drop of 0.05L (2% decline; IQR -5.6-1.8%, p<0.001); (Figure 1). A ≥10% decline in FEV1 occurred in 24/144 patients (17%) and an increase in FEV1 of >10% occurred in 6/151 (3%) of patients. Baseline demographics, lung function, disease severity, vaccination status and treatment type were not associated with a ≥10% decline in FEV1. CONCLUSION: In COVID optimized LTR with subsequent infection, the majority had mild disease. Reassuringly, most had stable lung function 2 months post infection. A small proportion had a decline in FEV1 of >10%, but there were no discernible risk factors to predict the decline. Published by Elsevier Inc. 2023-04 2023-04-03 /pmc/articles/PMC10068095/ http://dx.doi.org/10.1016/j.healun.2023.02.708 Text en Copyright © 2023 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ennis, S.L.
Levvey, B.
Shingles, H.
Holsworth, L.
Snell, G.
Gardiner, B.
(694) Preservation of Lung Function Despite Covid-19 Infection in a Cohort of Lung Transplant Recipients
title (694) Preservation of Lung Function Despite Covid-19 Infection in a Cohort of Lung Transplant Recipients
title_full (694) Preservation of Lung Function Despite Covid-19 Infection in a Cohort of Lung Transplant Recipients
title_fullStr (694) Preservation of Lung Function Despite Covid-19 Infection in a Cohort of Lung Transplant Recipients
title_full_unstemmed (694) Preservation of Lung Function Despite Covid-19 Infection in a Cohort of Lung Transplant Recipients
title_short (694) Preservation of Lung Function Despite Covid-19 Infection in a Cohort of Lung Transplant Recipients
title_sort (694) preservation of lung function despite covid-19 infection in a cohort of lung transplant recipients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068095/
http://dx.doi.org/10.1016/j.healun.2023.02.708
work_keys_str_mv AT ennissl 694preservationoflungfunctiondespitecovid19infectioninacohortoflungtransplantrecipients
AT levveyb 694preservationoflungfunctiondespitecovid19infectioninacohortoflungtransplantrecipients
AT shinglesh 694preservationoflungfunctiondespitecovid19infectioninacohortoflungtransplantrecipients
AT holsworthl 694preservationoflungfunctiondespitecovid19infectioninacohortoflungtransplantrecipients
AT snellg 694preservationoflungfunctiondespitecovid19infectioninacohortoflungtransplantrecipients
AT gardinerb 694preservationoflungfunctiondespitecovid19infectioninacohortoflungtransplantrecipients